Moreover, a history of prior TNF-alpha inhibitor use could potentially be a risk factor for AAA development given that 4 controls and 1 case had previously been treated with another TNF-alpha inhibitor, which may contribute to increased immunogenicity [26]. This evidence concerns the gene TNF and triple-A syndrome.